The FDA has changed the labeling for prescription famotidine (Pepcid tablets; Pepcid for oral suspension; Pepcid RPD orally disintegrating tablets; and Pepcid injection and Pepcid injection premixed; Merck & Co Inc, Whitehouse Station, NJ), indicated for short-term treatment and maintenance therapy for duodenal ulcer; short-term treatment of active benign gastric ulcer, gastroesophageal reflux disease (GERD), and esophagitis due to GERD; and treatment of pathological hypersecretory conditions.
Schwetz BA. Famotidine Labeling Change. JAMA. 2001;285(17):2186. doi:10.1001/jama.285.17.2186-JFD10004-3-1